Phase 1/1b study of telisotuzumab vedotin (Teliso-V) plus osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
JOURNAL OF CLINICAL ONCOLOGY(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要